Albiges L, et al. J Clin Oncol 36, 2018 (suppl 6S; abstr 577).
Adjuvant pembrolizumab versus observatie bij spierinvasief urotheelcarcinoom
feb 2025 | Immuuntherapie, Uro-oncologie
nov 2024 | Longoncologie
nov 2024 | Longoncologie
feb 2024 | Longoncologie
dec 2023 | Uro-oncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie